NCT06007924 2026-02-19
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06369259 2026-02-11
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06630260 2026-01-21
5G-RUBY
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT06487221 2025-11-04
Avutometinib and Defactinib in Diffuse Gastric Cancer
Columbia University
Phase 2 Recruiting
NCT05512208 2025-10-22
DURAFAK
University of Oklahoma
Phase 2 Recruiting
NCT06495125 2025-04-17
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting